Bristol-Myers Squibb Co
BRIEF: For the three months ended 31 March 2013, Bristol Myers Squibb Co. revenues decreased 27% to $3.83B. Net income applicable to common stockholders decreased 45% to $609M. Revenues reflect United States segment decrease of 44% to $1.97B. Net income also reflects Research and development increase of 9% to $930M (expense), Investment income decrease of 31% to $25M (income). Dividend per share increased from $0.34 to $0.35.
Common Stock $.10 Par, 06/11, 4.5B auth., 2,200,000,000 issd. less 500,000,000 shs. in Treas. @ $17.3B. Insiders own 0.17%. Stock issd. 11/89 in merger with Squibb. Basis: 2.4-for-1. Preferred Stock no Par, 10M auth., 5,268 issd. 3/10, 3/97, 2-for-1 stock splits. FY '99 - FY '01 finl's are restated due to change in acct. method.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
